Pfizer has discontinued the SUN 1120 Phase III trial evaluating Sutent in combination with prednisone for advanced castration-resistant prostate cancer (CRPC) that had progressed despite treatment with a docetaxel-based chemotherapy regimen. During a scheduled interim analysis, an independent Data Monitoring Committee (DMC) found that the combination of Sutent with prednisone was unlikely to improve overall survival when compared to prednisone alone. No new or unexpected safety issues were ident...